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Background
Biologic therapies targeting tumor necrosis factor alpha
(TNFa) are a mainstay in the treatment of autoimmune
diseases such as ankylosing spondylitis (AS), rheumatoid
arthritis (RA), or Crohn’s disease (CD). With increased
use of the biologic therapies, various adverse effects to
TNFa inhibitor have been reported.
Method
We reviewed retrospectively the clinical data of subject
who were treated with infliximab, adalimumab, or eta-
nercept from 2006 to 2012, and assessed the adverse
drug reactions using electronic medical recording sys-
tem in Pusan National University Hospital.
Results
In total, 111 subjects were enrolled. Mean age was
39.8¡¾11.7 years, and male was 68.5%. The diagnoses of
subjects were AS (62.2%), RA (24%), CD (17%), and pyo-
derma gangrenosum (0.9%). The injected agents were
adalimumab (53.2%), etanercept (29%), and infliximab
(20.7%). Adverse drug reactions of 30.6% were reported.
The most common adverse reactions were cutaneous
reactions; 10 (9.0%) eczema, 4 (3.6%) injection site reac-
tion, and 2 (1.8%) urticaria. 3.6% of subjects had a slight
increase in liver enzyme, and pulmonary tuberculosis
occurred in 2 (1.8%) patients. Mean therapy duration
prior to adverse reactions was 2.1¡¾2.2 years. Serious
adverse reaction, anaphylaxis, growth retardation, and
Henoch-Schönlein purpura occurred in one patient
each.
Conclusion
This study shows that the adverse reactions to TNFa
inhibitors were frequent, but most of them were mild
reactions and the most common adverse reaction was
cutaneous reactions.
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